These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29135645)

  • 21. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
    Kotera J; Mochida H; Inoue H; Noto T; Fujishige K; Sasaki T; Kobayashi T; Kojima K; Yee S; Yamada Y; Kikkawa K; Omori K
    J Urol; 2012 Aug; 188(2):668-74. PubMed ID: 22704456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
    Pomeranz HD
    Neurol Clin; 2017 Feb; 35(1):17-27. PubMed ID: 27886893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Moral Foundation for Anti-Doping: How Far Have We Progressed? Where Are the Limits?
    Murray TH
    Med Sport Sci; 2017; 62():186-193. PubMed ID: 28571014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PDE5 inhibitors: considerations for preference and long-term adherence.
    Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
    Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clean Olympians? Doping and anti-doping: the views of talented young British athletes.
    Bloodworth A; McNamee M
    Int J Drug Policy; 2010 Jul; 21(4):276-82. PubMed ID: 20056401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.
    Sanna F; Succu S; Boi A; Melis MR; Argiolas A
    J Sex Med; 2009 Oct; 6(10):2680-9. PubMed ID: 19678884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Can furosemide mask the use of performance-enhancing drugs?].
    Brinkman DJ; Tichelaar J; Van Agtmael MA
    Ned Tijdschr Geneeskd; 2021 May; 165():. PubMed ID: 34346634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recreational and ergogenic substance use and substance use disorders in elite athletes: a narrative review.
    McDuff D; Stull T; Castaldelli-Maia JM; Hitchcock ME; Hainline B; Reardon CL
    Br J Sports Med; 2019 Jun; 53(12):754-760. PubMed ID: 31097457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tadalafil alters energy metabolism in C2C12 skeletal muscle cells.
    Sabatini S; Sgrò P; Duranti G; Ceci R; Di Luigi L
    Acta Biochim Pol; 2011; 58(2):237-41. PubMed ID: 21681286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The sports psychiatrist and performance-enhancing drugs.
    Creado S; Reardon C
    Int Rev Psychiatry; 2016 Dec; 28(6):564-571. PubMed ID: 27310472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-performance sport, marijuana, and cannabimimetics.
    Hilderbrand RL
    J Anal Toxicol; 2011 Nov; 35(9):624-37. PubMed ID: 22080902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.
    Corona G; Rastrelli G; Burri A; Serra E; Gianfrilli D; Mannucci E; Jannini EA; Maggi M
    Andrology; 2016 Nov; 4(6):1002-1009. PubMed ID: 27636710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opinion paper: scientific, philosophical and legal consideration of doping in sports.
    Negro M; Marzullo N; Caso F; Calanni L; D'Antona G
    Eur J Appl Physiol; 2018 Apr; 118(4):729-736. PubMed ID: 29427238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
    Shindel AW
    J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doping in competition or doping in sport?
    Lippi G; Franchini M; Guidi GC
    Br Med Bull; 2008; 86():95-107. PubMed ID: 18385161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
    Sheweita SA; Wally M; Hassan M
    Oxid Med Cell Longev; 2016; 2016():4970906. PubMed ID: 27800121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of phosphodiesterase 5 inhibitors with concomitant medications.
    Corona G; Razzoli E; Forti G; Maggi M
    J Endocrinol Invest; 2008 Sep; 31(9):799-808. PubMed ID: 18997493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).
    Docherty JR
    Br J Pharmacol; 2008 Jun; 154(3):606-22. PubMed ID: 18500382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormone abuse in sports: the antidoping perspective.
    Barroso O; Mazzoni I; Rabin O
    Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use and misuse of hormones in sport.
    Sonksen PH; Cowan D; Holt RI
    Lancet Diabetes Endocrinol; 2016 Nov; 4(11):882-883. PubMed ID: 27542991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.